Ovarian Cancer, Volume 1This volume provides a complete overview of ovarian cancer. From cover to cover, it gives practical, timely advice on screening, diagnosis, and treatment. Ovarian cancer is the leading cause of death from gynecologic malignancies in the Western world. While substantial progress has been made, and more and more patients are living longer with the disease, the majority of patients with advanced ovarian cancer are not cured. Ovarian Cancer, a volume in the American Cancer Society Atlas of Clinical Oncology series, thoroughly discusses pathology, biology, epidemiology, genetics and screening. Specific chapters examine diagnosis and staging, surgical cytoreduction, and primary chemotherapy regimens. Renowned contributors lend their expertise to chapters on radiation therapy, early stage management, palliative surgery, and developmental and high-dose chemotherapy. Germ cell tumors and ovarian sex cord-stroma tumors are also examined. In addition, the text outlines the major progress made in the understanding of the biology of ovarian cancer and the molecular genetics of the disease. The majority of this atlas' authors are involved in the NCI-sponsored Specialized Programs in Research Excellence (SPORE) Program in Ovarian Cancer. |
Other editions - View all
Common terms and phrases
activity addition agents analysis associated benign borderline BRCA1 breast cancer Brenner tumor Cancer Res carboplatin cell tumors chemotherapy chromosome cisplatin Clin Oncol clinical colleagues combination common compared complete cycles cytoplasm detected disease dose drug early effect epithelial ovarian cancer et al evaluation evidence expression factor Figure function gene genetic Group growth factor Gynecol Oncol Gynecologic high-dose human identified important increased initial intraperitoneal involved levels loss malignant mg/m² months mucinous mutations normal Oncogene Oncol Oncology original ovar ovarian cancer ovarian carcinoma ovarian tumors ovary overall paclitaxel patients pelvic peritoneal phase positive potential present primary prognosis progression protein received recently receptor recurrent region reported residual disease response risk role screening serous shown shows significant stage suggested surface epithelium surgery surgical Table therapy tion toxicity treated treatment trial women